ASD Defiance Autism Impact ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 28.50 | Day Range | 28.10 – 28.17 |
| 52-Week Range | 24.59 – 28.52 | Volume | 453 |
| Avg Volume | 626 | AUM | $1.4M (Aug 26, 2026) |
| Expense Ratio | 0.79% | Yield (TTM) | 0.02% |
| NAV | 28.01 | Premium/Discount | +0.33% indicative |
| Inception | Jun 01, 2026 | Holdings | 40 |
| Issuer | Defiance | Exchange | NASDAQ |
| Category | Developed Markets | Index Tracked | Not stated in source data |
| CUSIP | 268961331 | ISIN | US2689613311 |
| Management | Not stated in source data | ||
About this ETF
It operates as an exchange-traded investment fund.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +5.73% | — | — | — | — | — | — | — | +15.82% |
| Total return | +5.71% | — | — | — | — | — | — | — | +15.85% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.79% | Annual cost of a $10,000 investment | $79.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 40 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Definium Therapeutics Inc | DFTX | 4.37% | 1.37K | $61.5K |
| 2 | Neuren Pharmaceuticals Ltd | NEU.AX | 4.06% | 3.55K | $57.2K |
| 3 | LifeStance Health Group Inc | LFST | 3.40% | 3.84K | $47.9K |
| 4 | Otsuka Holdings Co Ltd | 4578.T | 3.27% | 600 | $46.0K |
| 5 | ACADIA Pharmaceuticals Inc | ACAD | 3.23% | 1.54K | $45.5K |
| 6 | Repligen Corp | RGEN | 3.19% | 248 | $44.9K |
| 7 | Anavex Life Sciences Corp | AVXL | 3.04% | 13.22K | $42.8K |
| 8 | Revvity Inc | PKI | 2.89% | 326 | $40.7K |
| 9 | BioMarin Pharmaceutical Inc | BMRN | 2.81% | 594 | $39.6K |
| 10 | Bristol-Myers Squibb Co | BMY | 2.76% | 580 | $38.9K |
| 11 | AbbVie Inc | ABBV | 2.74% | 146 | $38.7K |
| 12 | Life Healthcare Group Holdings Ltd | LHC.JO | 2.73% | 53.49K | $38.5K |
| 13 | Roche Holding AG | ROP.SW | 2.73% | 82 | $38.5K |
| 14 | Medicover AB | MCOV-B.ST | 2.70% | 1.50K | $38.0K |
| 15 | Johnson & Johnson | JNJ | 2.65% | 138 | $37.3K |
| 16 | Acadia Healthcare Co Inc | ACHC | 2.62% | 1.33K | $36.9K |
| 17 | Bright Horizons Family Solutions Inc | BFAM | 2.62% | 506 | $36.9K |
| 18 | Takeda Pharmaceutical Co Ltd | 4502.T | 2.57% | 1.00K | $36.3K |
| 19 | Jazz Pharmaceuticals PLC | JAZZ | 2.53% | 140 | $35.6K |
| 20 | Pearson PLC | PSON.L | 2.52% | 2.18K | $35.5K |
| 21 | Teva Pharmaceutical Industries Ltd | TEVA.TA | 2.52% | 962 | $35.5K |
| 22 | Pfizer Inc | PFE | 2.51% | 1.26K | $35.4K |
| 23 | Eli Lilly & Co | LLY | 2.49% | 28 | $35.2K |
| 24 | Ipsen SA | IPN.PA | 2.46% | 182 | $34.7K |
| 25 | Novartis AG | NOVN.SW | 2.46% | 218 | $34.7K |
Click a ticker to see every ETF that owns it.
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.02% | Paid (last 12 months) | $0.0060 |
| Frequency | Irregular | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 24, 2026 | Last payment | $0.0060 (Jun 25, 2026) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 24, 2026 | Jun 24, 2026 | Jun 25, 2026 | $0.0060 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
Liquidity
| Volume today | 453 | Average volume | 626 |
| AUM | $1.4M | Premium/Discount | +0.33% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$9.0K | -0.64% | $1.4M → $1.4M |
| 1 Week | $14.8K | +1.07% | $1.4M → $1.4M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for ASD
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.